Skip to Main Content
Contact Us

Helping to Develop Cell Therapies 

January 15, 2025

Catalyst Oncology is a specialty oncology CRO devoting time, energy, and capital to supporting biotechs in bringing next-generation cell therapies to cancer patients in need. Oncology clinical research is complex, demanding, and continually evolving. Bringing effective cell therapies to proof-of-concept and then to market as fast as possible are our focus because every second counts for patients with cancer and their families.

Robust pipeline of cell therapy trials

  • Global footprint
    • North America, Europe, and APAC
  • Active trials with upwards of 200 patients
    and 30 sites
  • CAR-T, TILs, NK cells and vaccines
  • Autologous and allogeneic
  • Hematologic malignancies (NHL, MM, AML,
    DLBCL)
  • Solid tumors (ovarian, lung, pancreatic,
    colorectal, breast, GBM)

We understand the nuances of cell therapy trials

  • Logistics (autologous vs. allogeneic, apheresis coordination, chain of custody)
  • Safety/toxicity profiles (CRS, Neuro-toxicities)
  • LTFU/viral integration requirements
  • Training (site and team)
  • Regulatory approvals (IBC, ATMP)

Exclusively biotech-focused

  • A transparent people-first culture with industry-leading retention
  • We are responsive and attentive to the needs of both our customers and staff. Our industry-leading employee and project team retention guarantee program continuity, increased efficiency, and happy investigative sites.

Built to work exclusively with biotechs, our flexible processes and approach allow us to listen first, align goals, and execute with an eye toward rapid shifts when protocols amend or Breakthrough designations move a product straight from Phase I to registration.

Seasoned oncology experts  

With an average of 9+ years of oncology experience for key roles (PM, CTL, DM, Clinical Science), our oncology specialty guarantees you a seasoned team across all functions.

Additional differentiators 

Four additional differentiators for Catalyst Oncology listed horizontally with accompanying icons.

Active next-gen oncology experience

Working both locally and globally across Phases I through III in a range of solid tumor and hematologic indications, we understand the nuances of complex study designs, novel endpoints, and cutting-edge technologies. 

Wheels indicating the phase, indication, and drug classes of Catalyst Oncology experience.